BioMarCare

Tumor Biomarker Technologies for Early Cancer Diagnosis

Health Tech & Life Sciences
Non Active, Aug 2020 ceased to operate
Mature Jerusalem, Israel Founded 2002
LinkedIn
Last updated 2026-06-18
Total raised
$1.9M
Last: 2012-03
Stage
Mature
Founded
2002
Headcount
1
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

BioMarCare uses a multi-biomarker panel approach to generate molecular blood tests andtissue-based diagnostic (IHC) tests with high specificity and sensitivity for use in the early diagnosis of cancer. The companys Colon-MarCarePlex is an accurate, patient-friendly colorectal cancer screening test that measures the expression of several genes thatserve as biomarkers to detect colorectal cancer. It offers fast, affordable results with no bowel preparation, no diet or medication restrictions, and no handling of stool. Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early-stage colorectal cancer. BioMarCares MCRC-Strat is a semi-quantitative IHC assay using a protein biomarker combination designed to predict patient responses to drugs targeting the epidermal growth factor receptor. The product is being developed in collaboration with a U.S. partner.

Funding history · 3 rounds · $1.9M total

2012-03
$1.0M
2011-08
Grant $900K
2011-01
Undisclosed

Q&A

What is BioMarCare's primary focus?
BioMarCare specializes in tumor biomarker technologies for the early diagnosis of cancer, utilizing multi-biomarker panels for molecular blood tests and tissue-based diagnostic (IHC) tests.
What is the status of BioMarCare?
BioMarCare is currently inactive, having ceased operations in August 2020.
When was BioMarCare founded?
BioMarCare was founded in January 2002.
What is Colon-MarCarePlex?
Colon-MarCarePlex is BioMarCare's accurate, patient-friendly colorectal cancer screening test. It is a molecular assay (qRT-PCR) that measures the expression of several genes to detect advanced adenoma polyps and early-stage colorectal cancer.
What is MCRC-Strat?
MCRC-Strat is BioMarCare's semi-quantitative IHC assay that uses a protein biomarker combination to predict patient responses to drugs targeting the epidermal growth factor receptor. It is being developed in collaboration with a U.S. partner.
What was BioMarCare's last known funding round?
BioMarCare's last known funding round was in March 2012, raising $1,000,000 from Micromedic.
How much total funding has BioMarCare raised?
BioMarCare has raised a total of $1,900,000.
What is BioMarCare's employee count?
BioMarCare has 1-10 employees.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2B

Highlights

1 Patents

Tags

biomarkersblood-testoncologynon-invasivebiotechnologylaboratoriesmedical-technologiescancerhospitalsdetectiondiagnostics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/988311

Identifiers & details

Founded2002-1
Employees (exact)1
Status reasonNon Active, Aug 2020 ceased to operate